LPTX · Leap Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $161.0K | - | $1.25M | $10.54M | $12.91M | - | $14.91M | $17.89M | $11.30M | - |
| SG&A | $4.66M | - | $1.92M | $1.82M | $3.01M | - | $2.94M | $3.37M | $3.53M | - |
| Total Operating Expenses | $4.82M | - | $3.17M | $16.88M | $15.92M | - | $17.86M | $21.25M | $14.82M | - |
| D&A | - | - | - | - | - | - | - | - | $5.0K | - |
| Operating Income | ($4.82M) | - | ($3.17M) | ($16.88M) | ($15.92M) | - | ($17.86M) | ($21.25M) | ($14.82M) | - |
| Interest Expense | $7.0K | - | $10.0K | $7.0K | $6.0K | - | - | - | - | - |
| Income Tax | ($5.12M) | - | $202.0K | - | - | - | $708.0K | - | - | - |
| Net Income | ($77.17M) | - | ($3.30M) | ($16.64M) | ($15.44M) | - | ($18.18M) | ($20.13M) | ($13.82M) | - |
| EPS - Basic | ($0.46) | - | ($0.08) | ($0.40) | ($0.37) | - | ($0.44) | ($0.52) | ($0.51) | - |
| EPS - Diluted | ($0.46) | - | ($0.08) | ($0.40) | ($0.37) | - | ($0.44) | ($0.52) | ($0.51) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.69M | $14.04M | $9.69M | $18.13M | $32.71M | $47.25M | $62.82M | $78.48M | $54.92M | $70.64M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $516.0K | $1.98M | $4.28M | $7.34M | $6.36M | $4.74M | $5.95M | $7.81M | $5.95M | $6.46M |
| Current Assets | $81.92M | $162.08M | $10.50M | $19.16M | $33.87M | $48.04M | $63.81M | $79.59M | $56.19M | $71.60M |
| Total Assets | $87.38M | $163.18M | $11.40M | $20.04M | $34.88M | $49.12M | $65.05M | $81.43M | $57.96M | $72.83M |
| Current Liabilities | $3.00M | $4.56M | $8.70M | $14.32M | $14.04M | $14.08M | $16.09M | $15.60M | $10.44M | $12.68M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $3.00M | $9.68M | $14.08M | - | - | - | $16.09M | $15.64M | $10.59M | $12.68M |
| Stockholders' Equity | $84.38M | $153.51M | $2.69M | $5.72M | $20.84M | $35.05M | $48.95M | $65.79M | $47.37M | $60.14M |
| Retained Earnings | ($539.72M) | ($462.55M) | ($502.75M) | ($499.45M) | ($482.81M) | ($467.37M) | ($451.94M) | ($433.76M) | ($413.40M) | ($399.58M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.43M) | - | - | - | ($14.48M) | - | - | - | ($15.52M) | - |
| Investing Cash Flow | ($9.00M) | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $5.08M | - | - | - | ($61.0K) | - | - | - | $29.0K | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -88.3% | - | -29.0% | -83.0% | -44.3% | - | -27.9% | -24.7% | -23.8% | - |
| Return on equity | -91.5% | - | -122.6% | -291.1% | -74.1% | - | -37.1% | -30.6% | -29.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 27.28 | 35.56 | 1.21 | 1.34 | 2.41 | 3.41 | 3.97 | 5.10 | 5.38 | 5.64 |
| Quick ratio | 27.28 | 35.56 | 1.21 | 1.34 | 2.41 | 3.41 | 3.97 | 5.10 | 5.38 | 5.64 |
| Cash ratio | 2.23 | 3.08 | 1.11 | 1.27 | 2.33 | 3.36 | 3.90 | 5.03 | 5.26 | 5.57 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -688.1x | - | -316.6x | -2411.6x | -2652.8x | - | - | - | - | - |
| Equity multiplier | 1.04 | 1.06 | 4.23 | 3.51 | 1.67 | 1.40 | 1.33 | 1.24 | 1.22 | 1.21 |
| Liabilities / Assets | 0.03 | 0.06 | 1.23 | - | - | - | 0.25 | 0.19 | 0.18 | 0.17 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 69.7% | - | 82.3% | 20.6% | -7.4% | - | -20.4% | -44.9% | 65.3% | - |
| Net income growth (YoY) | -399.9% | - | 81.8% | 17.3% | -11.7% | - | -32.7% | -50.3% | 67.0% | - |
| EPS growth (YoY) | -24.3% | - | 81.8% | 23.1% | 27.5% | - | 13.7% | 42.9% | -59.4% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 304.9% | 338.0% | -94.5% | -91.3% | -56.0% | -41.7% | -32.0% | -21.7% | 67.2% | 2.2% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing LEAP THERAPEUTICS against the 5 most active filers in the same SIC group.